Harmony Biosciences Holdings, Inc. (HRMY) Revenue, Earnings & Financial Statements
$33.01NASDAQ: HRMYMarket Cap $1.94B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Harmony Biosciences Holdings, Inc. most recently reported annual revenue of $868.0M, net profit of $159.0M. Revenue grew at an average annual rate of 40.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Harmony Biosciences Holdings, Inc.: net profit was positive in 5 of 8 reported years; operating margin moved from -2433.8% to 24.0%, a shift of +2457.8 percentage points; the most recent year shows net profit of $159.0M.
Income Statement — 8 Years (USD millions)
Metric
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$6.0M
$160.0M
$305.0M
$438.0M
$582.0M
$715.0M
$868.0M
Operating Expenses
$41.0M
$152.0M
$143.0M
$218.0M
$318.0M
$390.0M
$524.0M
$660.0M
Operating Profit
−$41.0M
−$146.0M
$17.0M
$88.0M
$120.0M
$192.0M
$191.0M
$208.0M
Operating Margin
—
-2433.8%
10.6%
28.7%
27.4%
33.0%
26.7%
24.0%
Other Income
$2.0M
−$6.0M
−$54.0M
−$50.0M
−$15.0M
−$19.0M
$1.0M
$7.0M
Interest
$0
$6.0M
$28.0M
$24.0M
$19.0M
$24.0M
$17.0M
$15.0M
Depreciation
$0
$3.0M
$10.0M
$19.0M
$23.0M
$24.0M
$24.0M
$25.0M
Profit Before Tax
−$40.0M
−$152.0M
−$37.0M
$37.0M
$105.0M
$173.0M
$192.0M
$215.0M
Tax rate (%)
0.0%
0.0%
0.0%
7.6%
-73.3%
25.7%
24.1%
26.2%
Net Profit
−$40.0M
−$152.0M
−$37.0M
$35.0M
$181.0M
$129.0M
$145.0M
$159.0M
EPS
−$1.42
−$2.94
−$1.10
$0.58
$2.97
$2.13
$2.51
$2.71
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$168.0M
$155.0M
$173.0M
$186.0M
$201.0M
$185.0M
$200.0M
$239.0M
$244.0M
$215.0M
$261.0M
$269.0M
Operating Expenses
$128.0M
$103.0M
$151.0M
$124.0M
$146.0M
$128.0M
$152.0M
$174.0M
$205.0M
$178.0M
$172.0M
$215.0M
Operating Profit
$40.0M
$52.0M
$21.0M
$62.0M
$56.0M
$56.0M
$48.0M
$65.0M
$39.0M
$37.0M
$89.0M
$54.0M
Operating Margin
23.9%
33.6%
12.4%
33.2%
27.7%
30.4%
24.0%
27.4%
15.8%
17.3%
34.2%
20.1%
Interest
$5.0M
$5.0M
$4.0M
$4.0M
$4.0M
$4.0M
$4.0M
$4.0M
$4.0M
$3.0M
$3.0M
$3.0M
Profit Before Tax
$40.0M
$52.0M
$22.0M
$62.0M
$56.0M
$57.0M
$50.0M
$67.0M
$41.0M
$40.0M
$93.0M
$59.0M
Tax rate (%)
33.0%
26.0%
46.6%
25.9%
11.9%
20.3%
19.9%
24.6%
44.8%
18.1%
19.1%
18.7%
Net Profit
$27.0M
$38.0M
$12.0M
$46.0M
$49.0M
$46.0M
$40.0M
$51.0M
$22.0M
$32.0M
$75.0M
$48.0M
EPS
$0.45
$0.67
$0.20
$0.79
$0.85
$0.78
$0.68
$0.87
$0.38
$0.55
$1.28
$0.81
Over the 8 years reported for Harmony Biosciences Holdings, Inc., borrowings decreased from $324.0M in 2018 to $240.0M in 2025, cash stood at $753.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.60 times.
Balance Sheet — 8 Years (USD millions)
Metric
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$89.0M
$107.0M
$427.0M
$433.0M
$674.0M
$811.0M
$999.0M
$1.3B
Current Assets
$87.0M
$31.0M
$263.0M
$284.0M
$400.0M
$451.0M
$579.0M
$907.0M
Cash
$84.0M
$24.0M
$229.0M
$234.0M
$244.0M
$312.0M
$453.0M
$753.0M
Inventory
$0
$1.0M
$4.0M
$4.0M
$4.0M
$5.0M
$7.0M
$5.0M
Receivables
$0
$4.0M
$22.0M
$35.0M
$55.0M
$74.0M
$83.0M
$97.0M
Fixed Assets
$2.0M
$1.0M
$1.0M
$4.0M
$1.0M
$0
$3.0M
$5.0M
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$1.0M
$0
$0
$0
$102.0M
$114.0M
$123.0M
$130.0M
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$8.0M
$118.0M
$330.0M
$247.0M
$271.0M
$344.0M
$340.0M
$401.0M
Current Liabilities
$7.0M
$20.0M
$135.0M
$54.0M
$79.0M
$164.0M
$175.0M
$252.0M
Borrowings
$324.0M
$98.0M
$194.0M
$196.0M
$192.0M
$194.0M
$181.0M
$240.0M
Other Liabilities
$0
$20.0M
$136.0M
$51.0M
$79.0M
$151.0M
$159.0M
$162.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$82.0M
−$12.0M
$97.0M
$187.0M
$403.0M
$467.0M
$659.0M
$870.0M
For Harmony Biosciences Holdings, Inc., operating cash flow was positive in 5 of 8 reported years; free cash flow in the latest year was $348.0M; free cash flow was positive in 5 of 8 years; financing activities used $3.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 8 Years (USD millions)
Metric
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$39.0M
−$75.0M
−$3.0M
$99.0M
$144.0M
$219.0M
$220.0M
$348.0M
Investing Cash Flow
−$3.0M
−$127.0M
−$4.0M
−$101.0M
−$142.0M
−$47.0M
−$69.0M
−$40.0M
Financing Cash Flow
−$3.0M
$44.0M
$130.0M
$8.0M
$9.0M
−$104.0M
−$2.0M
−$3.0M
Net Cash Flow
−$19.0M
−$59.0M
$204.0M
$6.0M
$9.0M
$67.0M
$141.0M
$300.0M
Free Cash Flow
−$40.0M
−$76.0M
−$5.0M
$98.0M
$144.0M
$219.0M
$219.0M
$348.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
-2.22
EV / EBITDA
5.48
FCF Yield
16.27%
Quick Ratio
3.42
Interest Coverage
16.98
Return 1Y
-1.55%
Return 3Y
34.56%
Return 5Y
-19.54%
Harmony Biosciences Holdings, Inc. (HRMY) financials — frequently asked questions
What is Harmony Biosciences Holdings, Inc.'s annual revenue?
Harmony Biosciences Holdings, Inc. (HRMY) reported annual revenue of $868.0M in its most recent fiscal year.
What is Harmony Biosciences Holdings, Inc.'s net profit?
Harmony Biosciences Holdings, Inc. (HRMY) reported net profit of $159.0M in its most recent fiscal year.
What is HRMY EV/EBITDA?
Harmony Biosciences Holdings, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 5.48.
Revenue and earnings of other Biotechnology stocks